Huida Gene: HuidaGene Therapeutics: U.S. FDA AWARDS BOTH RARE PEDIATRIC DISEASE AND ORPHAN DRUG DESIGNATIONS TO HG204, A CRISPR RNA-EDITING THERAPY, FOR THE TREATMENT OF MECP2 DUPLICATION SYNDROME

Orphan Drug Designation (ODD) is a status that provides 7 years of post-approval protection and exemption from filing feesRare Pediatric Disease Designation (RPDD) qualified the Sponsor at the tim...